London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Maybe you should do some. All your comments are on one guy!!!!!
Clemenson
It's called research. Maybe you should do some on ROQ.
You'll only have to wait a few more months before all your arguments are proven to be null and void. I do still wonder what makes you spend so much time on a company that you're not even invested in.......hahahahha
Nothing better to do I guess
Watermelõn, I can always tell when I getting near the truth.
Ajan has done deals with Randox and Daiichi Sankyo, and worked for Roche.
Sausage is a shareholder in SYN and EDL.
Says it all really.
So has your research led you to invest or not invest. I wonder if not invest then why are you wasting your time
Meet me in London. I’ll give you a bare knuckle be.ating
The struck off dentist aspect, for me, is a red herring. It's irrelevant. If the governing body of your profession think you are so sh 1 t they strike you off, then you need a new career.
My concern is Ajan background in pharma, which I'm getting a feeling people don't want to discuss so focus on the struck of dentist aspect.
To me, your response has a feeling of sweeping it under the carpet.
I'm sure you are encouraging people to fully research companies they may wish to buy into, aren't you?
I'm only doing research in ROQ and asking questions, was you would do with any share you want to invest in. So not sure why you would bring up Edenville and SYN.
I'm sure you did research into ECO, 88E, AMC, VAL, MSYS, AA, UPL, BOIL or ROQ, didn't you?
Punjana.
Sausage
I think you should be more concerned with your investments in SYN and EDL.
If Ajan was good enough for Randox, Roche and Daiichi Sankyo then I don't think it matters if he isn't good enough for you lol.
Many thanks for popping your LSE clemenson cherry with a post for me. A question, if you are a member of the Twitterarti promoting this, which one?
Thank you for highlighting that the CEO would happily ring me back, as I build up my research into ROQ I may request a chat.
So when you say "article was written by someone very much apposed to stem cell research on religious grounds"
Which article?? How do you know they opposed stem cell research on religious ground? Is it written somewhere? Could you provide a link please? Or are you simply trying to claim they opposed stem cell research on religious grounds to deflect? Just be honest, is it your personal opinion of fact?
So if the author of some article yet to be identified was opposed to stem cell research on religious grounds, could you tell me if the authors of the following articles were also opposed to stem cell research on religious grounds when they wrote their articles?
https://forbetterscience .com/2019/07/15/questionable-activities-of-uk-company-celixir-by-patricia-murray/
https://forbetterscience.com/2019/04/04/sir-martin-and-ajan-the-stem-cell-gold-diggers/
https://www.walesonline.co.uk/business/business-news/struck-off-dentists-companies-funding-2025569
https://www.worcesternews.co.uk/news/7822615.dentist-struck-off-for-blunders/
https://the-eye.wales/doctor-at-large/
Surely they can't all be anti stem cell? Can they? I've certainly heard Ajan talk about anti stem cell people on Stockbox interview.
If you could let me know what due diligence ROQ undertook on Ajan I will add it to my research. To note, according to the Roquefort website the following are members of the Board (https://www.roquefortplc.com/board%20of%20directors)
Ajan Reginald
Dr Darrin Disley
Professor Sir Martin Evans
Stephen West
Jean Duvall
Dr Simon Sinclair
Dr Michael Stein
For Celixir (https://find-and-update.company-information.service.gov.uk/company/10541091/officers) it lists 13 officers / 8 resignations, so the remaining 5 are
Ajan Reginald (mentioned twice)
Dr Darrin Disley
Professor Sir Martin Evans
HURVITZ, Chaim
I would there therefore be really interested as to what due diligence Dr Darrin Disley and Professor Sir Martin Evans did on Ajan, who they worked with at Celixir before they made him CEO of ROQ. Think I may know the answer.
I wonder what due diligence they did of Ajan at Novacyt as, according to Ajan's LinkedIn page he was only there 1 year 1 month full time.
Looks like a few buys going through today. I wonder how long it take for the TR-1s to turn up as large shareholders potentially dispose of their shares?
I understand that you have your personal doubts, but the most obvious thing to look at is the recent Randox deal. The biggest diagnostics company in the UK and one of the Worlds leaders in its field has real reason to believe in the potential success of Roquefort and it's decision is based on science, not spurious articles written by who actually ?? Nobody I suspect
Sausage I believe he did address being struck of as a dentist in an interview, the excuse was an eye injury I believe. Not sure how you can treat multiple patients and not realize you have an eye problem but who knows.
But I will add it was some time ago and everyone deserves a second chance but it goes back to the same issue who is going to take on that gamble into a banking crisis, completely risk off at the moment.
Next set of results will also give us a clearer idea of their expenditure vs cash.
If you mail the PR company for ROQ with your doubts, and provided that you have a genuine interest in the company you will get a call from the CEO and he can answer all questions very easily. I'm an investor and have had such a conversation. The article was written by someone very much apposed to stem cell research on religious grounds and has been silenced by the threat of legal action. You should also consider the very extensive due diligence that the company researched on him prior to him being appointed CEO.
Read Fiona O'Leary's view on Ajan Reginald
https://twitter.com/fascinatorfun/status/1484634637246861319
The internet is just littered with articles on Ajan Reginald, Celixir, Greece trials, but I've never seen ROQ or Ajan offer a defence against the articles. Has anyone? Unless someone can post a link to an article where ROQ / Ajan respond?
Set of 5 tweets that bring together Ajan Reginald's work.
https://twitter.com/Aim_Eudaimonia/status/1638195199540166657
stockyinvest,
I agree re: credibility & management.
Having watched the IG.com interview with Ajan (https://www.youtube.com/watch?v=cvRtMDvdPLU) where he states (12m:45s) 'if ....... the data for the last 15 years is accurate' I continue to wonder where ROQ are going to get 15 years of data from. Does it include research from Celixir? Where Ajan previously worked.
I found these Editorial Expression of Concern (https://link.springer.com/article/10.1007/s12265-020-10076-7) for a paper that Ajan is a co-author. In which it states "Following an investigation into a number of concerns raised in relation to this article after publication, the journal has found that the study did not receive all necessary approvals from regulatory and ethical bodies......our investigation has found that advance approvals were not obtained from the National Ethics Committee nor the National Organizations for Medicines, as required for clinical trials conducted in Greece. "
The Editorial Expression of Concern also states "After reviewing the raw data, discrepancies can be found between the estimated and calculated LVEF data. As this raises questions about the accuracy of the method to determine whether patients met the inclusion criterion of an LVEF of less than 40%, the readers are advised to interpret the findings related to the baseline LVEF data with caution."
Celixir undertook these trial in Greece. So does the 15 years of data that Ajan refers to include the Greece trial that reportedly didn't have all necessary approvals from regulatory and ethical bodies and that readers are advised to interpret the findings related to the baseline LVEF data with caution?
A second Editorial Expression of Concern (EEoC) regarding a different paper that Ajan is a co-author. (https://www.researchgate.net/publication/348851881_Expression_of_Concern_STAT6_knockdown_using_multiple_siRNA_sequences_inhibits_proliferation_and_induces_apoptosis_of_human_colorectal_and_breast_cancer_cell_lines).
This EEoC states "Questions were raised post-publication as to whether the results and conclusions are adequately supported given that the experiments were conducted only in a single cell line per cancer type, lacked some controls, and sample sizes were low (as few as two replicates for some experiments). Questions were also raised about the validity of the statistical analyses reported in the article" and "A statistical reviewer reviewed the article and underlying dataset and raised concerns about the assumptions made about normality and equal variances. The article did not report evidence to support these assumptions or information about how the authors assayed for normality and equal variances."
Have a read of both Editorial Expression of Concerns
So I ask again, where does ROQ get 15 years of data from? For me it just doesn't add up.
Looks like the Twitterarti are back pushing this tonight. Wonder what they are expecting over the next couple of days?
Unfortunately sausage there is no credibility here for many reasons but the most prominent is management, no smart investor will take on so much risk in this climate if it fails at the first hurdle.
More importantly what is their cash burn now with so many fingers in so many pies.
Having watched the IG.com interview with Ajan (https://www.youtube.com/watch?v=cvRtMDvdPLU) where he states (12m:45s) 'if ....... the data for the last 15 years is accurate'
If!!!!!
With Roquefort Investments being incorporated on the 17 Aug 2020 and Roquefort Investments becoming Roquefort Therapeutics on the 30 Dec 2021 (Filing History https://find-and-update.company-information.service.gov.uk/company/12819145). Where has Ajan got 15 years of data from? And why is he saying 'if it is accurate'? Surely you would know about your own data from 3 , 4 , 5... 10 years ago because the data had been independently verified and the test repeatable?
Does Ajan have doubt over Roquefort Therapeutics data? Why is no lab data / peer reviewed data being released? Deals with Randox to do more research and an Advisory Board to advise, but has ROQ produced anything substantial yet?
I'm even more nervous about ROQ after hearing Ajan say 'if ....... the data for the last 15 years is accurate'
.....we consider it a sell off?
It's clean and refers to ROQ
https://twitter.com/Spectre_Returns/status/1633604451100401704
Seems he’s better at pulling money out of people’s pockets than pulling teeth out.
Feel sorry for all those that bought in on the hype. It’s a nothing share.
You are right sausage just looked on twitterarti as you call it and it is getting desperate dentist CEO is now linking articles of $200million MRNA deals and implying it to ROQ, not sure on ethicality of that but it stinks.
All these non event deals and appointments must be having an effect on cash position, next report will be interesting.